Chemistry:Aprocitentan

Short description: Chemical compound

Aprocitentan

Clinical data
Other names	ACT-132577
ATC code	C02KN01 (WHO)
Identifiers
IUPAC name 5-(4-Bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
CAS Number	1103522-45-7
PubChem CID	25099191
IUPHAR/BPS	10070
DrugBank	DB15059
ChemSpider	25027753
UNII	MZI81HV01P
KEGG	D11441
ChEBI	CHEBI:76609
ChEMBL	ChEMBL2165326
Chemical and physical data
Formula	C16H14Br2N6O4S
Molar mass	546.19 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br
InChI InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24) Key:DKULOVKANLVDEA-UHFFFAOYSA-N

Aprocitentan is an endothelin receptor antagonist active at both endothelin A and endothelin B receptors. It is developed for resistant hypertension by Idorsia, which sold it to Janssen but purchased the rights back in 2023 for $343 million.

Aprocitentan is an active metabolite of macitentan.